AML with BCR-ABL1 Fusion treated with Imatinib, a Hypomethylating Agent and Venetoclax. (2022)

• Record Type: Journal Article
• Authors: Low, Soon Khai; Nanua, Suparna; Patel, Mehul; Renteria, Anne S
• Is Part Of: Leukemia research reports. Volume 17(2022)
• Publication Date: 2022
• Subjects: Acute myeloid leukemia -- Philadelphia chromosoome -- Decitabine -- Venetoclax -- Tyrosine kinase inhibitor; Leukemia -- Periodicals; Lymphomas -- Periodicals; Multiple myeloma -- Periodicals; Leukemia -- Periodicals; Lymphoma -- Periodicals; Multiple Myeloma -- Periodicals; Hematologic Neoplasms -- Periodicals; Leukemia; Lymphomas; Multiple myeloma; Electronic journals; Periodicals; 616.9941905
• DOI: 10.1016/j.lrr.2022.100333
• Languages: English
• ISSNs: 2213-0489

Abstract

Abstract: A patient with history of myelodysplastic syndrome (MDS) presented with multifocal pneumonia and was found to have Philadelphia chromosomepositive (Ph+) acute myeloid leukemia (AML). A tyrosine kinase inhibitor (TKI) was added to decitabine and venetoclax combination, providing a molecular and cytogenetic complete response despite additional cytogenetic and molecular abnormalities. She remains in remission after eleven cycles of treatment. Our report describes the tolerability and success of a triplet regimen that incorporates a TKI to a backbone of decitabine and venetoclax in a patient with high-risk disease and with significant comorbidities.